RxDoctor Payments DataLook up a doctor →

Kurian Abraham, MD

Geriatric Psychiatry · Charlotte, NCNPI 1891754297

Payments from drug & device makers

$5,635,026in general payments, 2019–2025

Across 1,039 payments — averaging $5423.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.6M
  • Teva Pharmaceuticals USA, Inc.$1.2M
  • Sunovion Pharmaceuticals Inc.$689K
  • Janssen Research & Development, LLC$554K
  • Sage Therapeutics, LLC$410K
  • Sumitomo Pharma America, Inc.$370K
  • plus $792K from 25 others
$286in research payments, 2019–2025

Across 3 payments — averaging $95.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$286

What the payments were for

  • Consulting fees$2003%
  • Food & beverage$6,90394%
  • Education$2483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric psychiatry providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$38,504
Medicare patients
48
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine28$331,110
Austedo XrDeutetrabenazine26$158,796
Abilify MaintenaAripiprazole35$99,296
VraylarCariprazine Hcl56$96,480
AuvelityDextromethorphan Hbr/Bupropion40$43,428
Invega SustennaPaliperidone Palmitate14$39,222
NuedextaDextromethorphan Hbr/Quinidine15$25,991
CaplytaLumateperone Tosylate13$25,148
TrintellixVortioxetine Hydrobromide24$15,516
BelsomraSuvorexant31$14,220
SpravatoEsketamine Hcl13$14,106
Paliperidone ErPaliperidone25$6,967
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$2,221
Memantine Hcl38$1,787
Prazosin Hcl61$1,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,198,990$489,90654 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,204$99,29635 claims
AbbVieVraylar$1,621,731$96,48056 claims
Johnson & JohnsonInvega Sustenna, Spravato$413$53,32827 claims
Axsome Therapeutics, Inc.Auvelity$575$43,42840 claims
Avanir Pharmaceuticals, Inc.Nuedexta$44,011$25,99115 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$214,135$25,14813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$87$15,51624 claims
Almatica Pharma LLCSertraline Hcl$38$13627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric psychiatry providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other geriatric psychiatry in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →